- Home
- OPFI vs INBX Comparison
OPFI vs INBX Comparison
Compare OPFI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- INBX
- Stock Information
- Founded
- OPFI 2009
- INBX 2010
- Country
- OPFI United States
- INBX United States
- Employees
- OPFI N/A
- INBX N/A
- Industry
- OPFI Finance: Consumer Services
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- INBX Health Care
- Exchange
- OPFI Nasdaq
- INBX Nasdaq
- Market Cap
- OPFI 205.2M
- INBX 178.5M
- IPO Year
- OPFI N/A
- INBX 2020
- Fundamental
- Price
- OPFI $12.43
- INBX $11.28
- Analyst Decision
- OPFI Buy
- INBX Hold
- Analyst Count
- OPFI 2
- INBX 1
- Target Price
- OPFI $11.75
- INBX N/A
- AVG Volume (30 Days)
- OPFI 866.2K
- INBX 94.2K
- Earning Date
- OPFI 05-07-2025
- INBX 05-20-2025
- Dividend Yield
- OPFI 1.99%
- INBX 7.45%
- EPS Growth
- OPFI N/A
- INBX N/A
- EPS
- OPFI N/A
- INBX 112.62
- Revenue
- OPFI $305,566,000.00
- INBX $200,000.00
- Revenue This Year
- OPFI $112.50
- INBX N/A
- Revenue Next Year
- OPFI $7.84
- INBX N/A
- P/E Ratio
- OPFI N/A
- INBX $0.10
- Revenue Growth
- OPFI 31.46
- INBX N/A
- 52 Week Low
- OPFI $2.82
- INBX $10.80
- 52 Week High
- OPFI $17.73
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- OPFI 76.20
- INBX 41.19
- Support Level
- OPFI $11.30
- INBX $10.90
- Resistance Level
- OPFI $12.30
- INBX $11.98
- Average True Range (ATR)
- OPFI 0.50
- INBX 0.85
- MACD
- OPFI 0.38
- INBX -0.02
- Stochastic Oscillator
- OPFI 94.31
- INBX 19.75
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.